Equillium, Inc.
About Equillium, Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $41.1M
- Net income
- -$22.4M
- Total assets
- $31.9M
- Market cap
- $185.9M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $23.6M
- Operating income
- -$23.6M
- Income tax
- $0
- Net income
- -$22.4M
- EPS (basic)
- $-0.39
- EPS (diluted)
- $-0.39
Balance sheet
- Total assets
- $31.9M
- Current assets
- $31.0M
- Total liabilities
- $3.3M
- Current liabilities
- $2.9M
- Shareholders’ equity
- $28.6M
Cash flow
- Operating cash flow
- -$22.7M
- Investing cash flow
- $4.5M
- Financing cash flow
- $30.4M
- Net cash flow
- $12.1M
Statements via Polygon.io (SEC filings)
- Market cap
- $185.9M
- EPS (diluted)
- $-0.39
- Dividend yield
- 99.28%
- Shares outstanding
- 67.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 12, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $22.4M in FY2024.
- Trading 13% below its 52-week high.
- Pays a dividend yielding about 99.28% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Equillium, Inc..
Write a review
News about Equillium, Inc.
News & sentiment via Polygon.io
